Constantine S Mitsiades, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Constantine Mitsiades and Irene Ghobrial.
Connection Strength
0.938
-
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
Score: 0.153
-
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
Score: 0.120
-
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
Score: 0.041
-
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
Score: 0.039
-
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
Score: 0.035
-
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
Score: 0.033
-
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer. 2012 Sep; 15(3):273-82.
Score: 0.032
-
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
Score: 0.031
-
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
Score: 0.031
-
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
Score: 0.030
-
Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
Score: 0.030
-
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
Score: 0.030
-
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
Score: 0.029
-
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
Score: 0.027
-
The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
Score: 0.027
-
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
Score: 0.027
-
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
Score: 0.027
-
Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
Score: 0.026
-
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
Score: 0.026
-
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
Score: 0.026
-
Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
Score: 0.026
-
The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
Score: 0.024
-
Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
Score: 0.024
-
The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
Score: 0.022
-
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.